Arcus Biosciences assumed with a Buy at Citi. Citi analyst Yigal Nochomovitz assumed coverage of Arcus Biosciences with a Buy rating and $25 price target. The analyst sees an attractive risk/reward profile ahead of clinical data from the company’s chemo/PD-1 combo trials in multiple cancers with lead compound AB928 in mid and the second half of 209. He sees potential for 5%-10% upside from each of three key data events expected in 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.